adg106
mAbexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 17, 2018 (NCT03707093)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
TNFRSF9 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05491083 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2022 | Adagene Inc, Merck, National University of Singapore |
| NCT05275777 | Phase 1/Phase 2 (Phase 2) | May 19, 2022 | Adagene Inc, National University of Singapore |
| NCT05236608 | Phase 1/Phase 2 (Phase 2) | Nov 12, 2021 | Adagene Inc, Bristol-Myers Squibb, National University of Singapore, Singapore Translational Cancer Consortium |
| NCT04775680 | Phase 1/Phase 2 (Phase 2) | Mar 11, 2021 | Adagene Inc |
| NCT03802955 | Phase 1 | Dec 20, 2018 | Adagene Inc |
| NCT03707093 | Phase 1 | Sep 17, 2018 | Adagene Inc |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adagene Inc | For profit | 6 | 3 | 2 | 2018 |
| National University of Singapore | Academic/Hospital | 3 | 3 | 1 | 2021 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
| Singapore Translational Cancer Consortium | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1